B-cell malignancies as a model for cancer vaccines: From prototype protein to next generation genetic chemokine fusions

Immunological Reviews

Volumn 170, Issue , 1999, Pages 115-126

  Biragyn, Arya ^a   Kwak, Larry W ^a  

^a Medicine Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN; TUMOR ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; B CELL LYMPHOMA; CELLULAR IMMUNITY; DRUG POTENCY; EFFECTOR CELL; GENE FUSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN VARIABLE REGION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINE PRODUCTION;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; BASE SEQUENCE; CANCER VACCINES; CHEMOKINES; DNA PRIMERS; HUMANS; LYMPHOMA, B-CELL; MICE; RECEPTORS, CHEMOKINE; RECOMBINANT FUSION PROTEINS; VACCINES, DNA;

EID: 0032861901     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01333.x     Document Type: Review

References (97)

1. 1. Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci USA 1971;68:3130-3135.
2. 2. Lynch RG, Craff RG, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 1972;69:1540-1544.
3. 3. Kobrin CB, Kwak LW. Development of vaccine strategies for the treatment of B-cell malignancies. Cancer Invest 1997;15:577-587.
4. 4. Kaminski MS, Kitamura K, Maloney DG, Levy R. Idiotype vaccination against murine B cell lymphoma, inhibition of tumor immunity by free idiotype protein. J Immunol 1987;138:1289-1296.
5. 5. Bianchi A, Massaia M. Idiotypic vaccination in B-cell malignancies. Mol Med Today 1997;3:435-441.
6. 6. Chen TT, Tao MH, Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994;153:4775-4787.
7. 7. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 1996;93:10972-10977.
8. 8. Biragyn A, Tani K, Grimm MC, Weeks SD, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17:253-258.
9. 9. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-1215.
10. 10. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 1996;93:10972-10977.
11. 11. Wolff JA, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
12. 12. Haynes JR, McCabe DE, Swain WF, Widera G, Fuller JT. Particle-mediated nucleic acid immunization. J Biotechnol 1996;44:37-42.
13. 13. Davis HL. Plasmid DNA expression systems for the purpose of immunization. Curr Opin Biotechnol 1997;8, 635-640.
14. 14. Hawkins RE, Winter G, Hamblin TJ, Stevenson FK, Russell SJ. A genetic approach to idiotypic vaccination. J Immunotherapy 1993;14:273-278.
15. 15. Watanabe A, et al. Induction of antibodies to a κV region by gene immunization. J Immunol 1993;151:2871-2876.
16. 16. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997;158:2278-2284.
17. 17. Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996;156:2369-2375.
18. 18. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997;158:3635-3639.
19. 19. Weiner GJ, Liu H M, Wooldridge JE, Dahle CE, Kreig AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are selective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997;94:10833-10837.
20. 20. Sato Y, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-354.
21. 21. Skerra A, Plückthun A. Assembly of a functional immunoglobulin F, fragment in Escherichia coli. Science 1988;240:1038-1040.
22. 22. Huston JS, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85:5879-5883.
23. 23. Huston JS, et al. Protein engineering of single-chain Fv analogs and fusion proteins. In: Langone JJ, ed. Methods in enzymology. New York: Academic Press; 1991. p. 46-98.
24. H segments with different hypervariable loops. J Mol Biol 1992;227:776-798.
25. 25. Matsuda F, et al. Structure and physical map of 64 variable segments in the 3' 0.8-megabase region of the human immunoglobulin heavy-chain locus. Nat Genet 1993;3:88-94.
26. 26. Williams SC, Frippiat JP, Tomlinson IM, Ignatovich O, Lefrane M-P, Winter G. Sequence and evolution of the human germline Vλ repertoire. J Mol Biol 1996;264:220-232.
27. 27. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 1995;145:211-228.
28. 28. Orlandi R, Güssow DH, Jones PT, Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:3833-3837.
29. 29. Dattamajumdar AK, Jacobson DP, Hood LE, Osman GE. Rapid cloning of any rearranged mouse immunoglobulin variable genes. Immunogenetics 1996;43:141-145.
30. 30. Doenecke A, Winnacker E-L, Hallek M. Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines. Leukemia 1997;11:1787-1792.
31. 31. Whitlow M, Filpula D. Single-chain Fv proteins and their fusion proteins. Methods 1991;2:97-105.
32. 32. Evans GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cel Biol 1985;5:3610-3616.
33. 33. Hopp TP, et al. A short polypeptide marker sequence useful for recombinant protein identification and purification. Biotechnology (N Y) 1988;6:1204-1210.
34. 34. Janknecht R, de Martynoff G, Lou J, Hipskind RA, Nordheim A, Stunnenberg HG. Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus. Proc Natl Acad Sci USA 1991;88:8972-8976.
35. 35. Bergmanm Y, Haimovich J. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eb origin. J Immunol 1977;7:413-417.
36. 36. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 1979;122:549-554.
37. 37. Kortt AA, et al. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur J Biochem 1994;221:151-157.
38. 38. Buchner J, Pastan I, Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 1992;205:263-270.
39. 39. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996;2:1038-1041.
40. 40. Reitan SK, Hannestad K. A syngeneic idiotype is immunogenic when borne by IgM but tolerogenic when joined to IgG. Eur J Immunol 1995;25:1601-1608.
41. 41. Oppenheim JJ, Gery I. From lymphodrek to interleukin 1 (IL-1). Immunol Today 1993;14:232-234.
42. 42. Rao KV Nayak AR. Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human interleukin 1. Proc Natl Acad Sci USA 1990;87:5519-5522.
43. 43. Beckers W, et al. Increasing the immunogenicity of protein antigens through the genetic insertion of VQGEESNDK sequence of human IL-1β into their sequence. J Immunol 1993;151:1757-1764.
44. 44. Hakim I, Levy S, Levy R. A nine-amino acid peptide from IL-1β augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996;157:5503-5511.
45. 45. Kopp EB, Medzhitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 1999;11:13-18.
46. 46. Colaco CA. Towards a unified theory of immunity: dendritic cells, stress proteins and antigen capture. Cell Mol Biol. 1998;44:883-890.
47. 47. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 1998;161:2428-2434.
48. 48. Harty JT, Lenz LL, Bevan MJ. Primary and secondary immune responses to Listeria monocytogenes. Curr Opin Immunol 1996;8:526-530.
49. 49. King CA, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998;4:1281-1286.
50. 50. Manning LS, Berger JD, O'Donoghue HL, Sheridan GN, Claringbold PG, Turner JH. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 1992;66:1088-1093.
51. 51. Vanderkerken K, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer 1997;76:451-460.
52. 51. Falo LD Jr, Storkus WJ, Giving DNA vaccines a helping hand. Nat Med 1998;4;1239-1240.
53. 53. Stevens TL, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988;334:255-258.
54. 54. Bogen B, Weiss S. Processing and presentation of idiotypes to MHC-restricted T cells. Int Rev Immunol 1993;10:337-355.
55. + T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 1993;148:177-188.
56. 56. McWilliam AS, et al. Dendritic cells are recruited into the airway epithelium during the inflammatory response to a broad spectrum of stimuli. J Exp Med. 1996;184:2429-2432.
57. 57. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991;67:1033-1036.
58. 58. Rollins BJ. Chemokines. Blood 1997;90:909-928.
59. 59. Haelens A, Wuyts A, Proost P, Struyf S, Opdenakker G, Van DJ. Leukocyte migration and activation by murine chemokines. Immunobiology 1996;195:499-521.
60. 60. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445.
61. 61. Sozzani S, et al. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol 1995;155:3292-3295.
62. 62. Xu LL, Warren MK, Rose WL, Gong W, Wang JM. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J Leukoc Biol 1996;60:365-371.
63. 63. Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 1998;161:3096-3102.
64. 64. Prado GN, Suzuki H, Wilkinson N, Cousins B, Navarro J. Role of the C terminus of the interleukin 8 receptor in signal transduction and internalization. J Biol Chem 1996;271:19186-19190.
65. 65. Solari R, et al. Receptor-mediated endocytosis of CC chemokines. J Biol Chem 1997;272:9617-9620.
66. 66. Signoret N, et al. Phorbol esters and SDF-1 induce rapid endocytosis and down modulation of the chemokine receptor CXCR4. J Cell Biol 1997;139:651-664.
67. 67. Sallusto F, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998;28:2760-2769.
68. 68. Sozzani S, et al. Differential regulation of chemokine receptors during dendritic cell maturation; a model for their trafficking properties. J Immunol 1998;161:1083-1086.
69. 69. Dieu MC, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373-386.
70. 70. Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, Austyn JM. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med 1995;181:2237-2247.
71. 71. Thirion S, Nys G, Fiten P, Masure S, Van Damme J, Opdenakker G. Mouse macrophage derived monocyte chemotactic protein-3: cDNA cloning and identification as MARC/FIC. Biochem Biophys Res Commun 1994;201:493-499.
72. 72. Weissman D, Rubbert A, Combadiere C, Murphy PM, Fauci AS. Dendritic cells express and use multiple HIV coreceptors. Adv Exp Med Biol 1997;417:401-406.
73. 73. Rubbert A, et al. Dendritic cells express multiple chemokine receptors used as coreceptors for HIV entry. J Immunol 1998;160:3933-3941.
74. 74. Kacani L, et al. Dendritic cells transmit human immunodeficiency virus type 1 to monocytes and monocyte-derived macrophages. J Virol 1998;72:6671-6677.
75. 75. Delgado E, Finkel V, Baggiolini M, Mackay CR, Steinman RM, Granelli-Piperno A. Mature dendritic cells respond to SDF-I, but not to several β-chemokines. Immunobiology 1998;198:490-500.
76. 76. Luster AD, Leder P. IP-10, a -C-X-C-chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993;178:1057-1065.
77. 77. Strieter RM, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348-27357.
78. 78. Ohmori Y, Hamilton TA. A macrophage LPS-inducible early gene encodes the murine homologue of IP-10. Biochem Biophys Res Commun 1990;168:1261-1267.
79. 79. Kipps T, Mendoza R. Extending genetic vaccines with chemokines. Nat Biotechnol 1999;17:226-227.
80. 80. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9:551-562.
81. 81. D'Souza MP, Harden VA. Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. Nat Med 1996;2:1293-1300.
82. 82. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985;4:191-209.
83. 83. Weiner GJ, Kaminski MS. Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma. J Immunol 1990;144:2436-2445.
84. 84. Thielemans K, Rothbard JB, Levy S, Levy R. Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens. J Exp Med 1985;162:19-34.
85. 85. Campbell MJ, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987;139:2825-2833.
86. 86. Carroll WL, Starnes CO, Levy R, Levy S. Alternative V κ gene rearrangements in a murine B cell lymphoma. An explantation for idiotypic heterogeneity. J Exp Med 1988;168:1607-1620.
87. 87. Bartnes K, Hannestad K. Engagement of the B lymphocyte antigen receptor induces presentation of intrinsic immunoglobulin peptides on major histocompatibility complex class II molecules. Eur J Immunol 1997;27:1124-1130.
88. 88. Sato K, Ochi A. Inhibition of B-cell receptor-antigen complex internalization by FcγRHB1 signals. Immunol Lett 1998;61:135-143.
89. 89. Dyke RJ, McBride H, George AJ, Hamblin TJ, Stevenson FK. Idiotypic vaccination against B cell lymphoma leads to dormant tumour. Cell Immunol 1991;132:70-83.
90. 90. Tutt AL, et al. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol 1998;161:3176-3185.
91. 91. Krolick KA, Isakson PC, Uhr JW, Vitetta ES. BCL1, a murine model for chronic lymphocytic leukemia: use of the surface immunoglobulin idiotype for the detection and treatment of tumor. Immunol Rev 1979;48:81-106.
92. 92. Krolick KA, Isakson PC, Uhr JW, Vitetta ES. Murine B cell leukemia (BCL1): organ distribution and kinetics of growth as determined by fluorescence analysis with an anti idiotypic antibody. J Immunol 1979;123:1928-1935.
93. 93. Manetti C, Rouvier E, Gautherot E, Loucif E, Barbet J, Le Doussal JM. Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens. Int J Cancer 1997;71:1000-1009.
94. 94. Knapp MR, et al. Simultaneous expression of immunoglobulin μ and δ heavy chains by a cloned B-cell lymphoma: a single copy of the VH gene is shared by two adjacent CH genes. Proc Natl Acad Sci USA 1982;79:2996-3000.
95. 95. Kwak LW, Pennington R, Boni L, Ochoa AC, Robb RJ, Popescu MC, Liposomal formulation of self lymphoma antigen induces potent antitumor immunity J Immunol 1998;160:3637-3641.
96. 96. Levitsky HI, et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858-3865.
97. 97. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997;89:3806-3816.